Physician profile
Brett Nowlan
NPI 1861688772
$797,665.31
in general payments reported to CMS, 2019-2025
37 companies · $119K in 2025
The $119K reported for 2025 was more than what 99% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $175K · 2020: $73K · 2021: $109K · 2022: $79K · 2023: $90K · 2024: $153K · 2025: $119K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $301K · Travel and Lodging: $49K · Food and Beverage: $12K · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $301,113.94 |
| Travel and Lodging | $48,759.26 |
| Food and Beverage | $12,429.76 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $165,884.28 | 2019-2025 | Repatha, Repatha |
| Novo Nordisk INC | $137,643.18 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Esperion Therapeutics, INC. | $125,802.92 | 2020-2025 | Nexletol, Nexlizet |
| Amarin Pharma, INC. | $115,105.46 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $84,431.92 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76,677.67 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $65,307.54 | 2020-2025 | Jardiance, Zepbound |
| Regeneron Healthcare Solutions, INC. | $15,967.62 | 2019-2024 | Evkeeza |
| Janssen Pharmaceuticals, INC | $4,906.95 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $895.47 | 2019-2025 | |
| Pfizer INC. | $690.34 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $557.53 | 2019-2025 | Farxiga |
| Heartflow, INC. | $535.28 | 2022-2025 | Ffrct |
| Abbott Laboratories | $460.31 | 2022-2025 | Cardiomems, Freestyle Libre 3 |
| Boston Scientific Corporation | $416.55 | 2022-2024 | Watchman Flx, Watchman Access System |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brett Nowlan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.